ArticleClinical & experimental metastasis2013
Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy.
Article in Clinical & experimental metastasis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Sarcoma metastasis: distinct biological principles beyond the carcinoma paradigm.Cancer metastasis reviews · 2026Review
- Advancement in Scaffold-Based 3D Cell Culture Models for Osteosarcoma Drug Screening.ACS biomaterials science & engineering · 2025Review
- Impact of scaffold material choice on osteosarcoma phenotype and drug responses in 3D.Acta biomaterialia · 2025Article
- Gene Expression Profiling and Phenotypic Characterization of Circulating Tumor Cells Derived from a Murine Osteosarcoma Model.Cancers · 2025Article
- Exploring the effects of taurolidine on tumor weight and microvessel density in a murine model of osteosarcoma.Oncology research · 2024Article
- Engineered bone marrow as a clinically relevant ex vivo model for primary bone cancer research and drug screening.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Inhibitory effect of aspirin on inflammation-induced lung metastasis of cancer cells associated with neutrophil infiltration.Surgery today · 2023Article
- The splicing factor YBX1 promotes the progression of osteosarcoma by upregulating VEGFHeliyon · 2023Article
- Enumeration and Characterization of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.International journal of molecular sciences · 2023Article
- The role of hypoxia and radiation in developing a CTCs-like phenotype in murine osteosarcoma cells.Frontiers in cell and developmental biology · 2023Article
- Osteosarcoma mechanobiology and therapeutic targets.British journal of pharmacology · 2022Review
- Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study.Investigational new drugs · 2021Article
- Current research progress in targeted anti-angiogenesis therapy for osteosarcoma.Cell proliferation · 2021Review
- Targeting the VEGF Pathway in Osteosarcoma.Cells · 2021Review
- Characterization of a Novel Murine Colon Carcinoma Subline with High-Metastatic Activity Established by In Vivo Selection Method.International journal of molecular sciences · 2020Article
- Polymer-mediated gene therapy: Recent advances and merging of delivery techniques.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression.Frontiers in oncology · 2020Review
- Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Low-dose eribulin reduces lung metastasis of osteosarcomaOncotarget · 2019Article
- Relevance of 3d culture systems to study osteosarcoma environment.Journal of experimental & clinical cancer research : CR · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is the most common malignant bone tumor and the prognosis depends on pulmonary metastases, which arise from multi-step progression of malignant tumors. We herein aimed to clarify the critical step of pulmonary metastasis using the syngeneic mouse spontaneous highly metastatic OS LM8 and parental Dunn cell lines, to identify new candidate molecules to suppress pulmonary metastasis. We first investigated the chronological detection of circulating tumor cells (CTCs) from mice with either cell line. LM8 CTCs appeared faster, at a higher rate and with a greater number compared to Dunn CTCs. Cultured cells from CTCs of LM8 showed higher proliferative ability than cells from the primary site in suspension culture, which mimicked the environment of the bloodstream for CTCs. The proliferative ability of LM8 cells was also higher than that of Dunn cells in 3D collagen culture with low stiffness (-150 Pa; close to conditions in the lung). We next focused on the extravasation step. LM8 showed higher migration ability compared to Dunn with transendothelial migration assay. We also found a disruption in endothelial barrier function throughout co-culture with LM8 using time-lapse imaging. In addition, LM8 secreted high levels of vascular endothelial growth factor (VEGF), while VEGF signal inhibition with a small molecule tyrosine kinase inhibitor (pazopanib) decreased disruption of the vascular barrier and transendothelial migration of LM8. Finally, daily oral administration of pazopanib reduced the rate and size of pulmonary metastasis in vivo. Collectively, these results show anti-VEGF therapy as a candidate for pulmonary metastasis of OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.